Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-701 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| TERN-701 | DRUG | TERN-701 orally QD |
TERN-701 is an investigational oral therapy being developed for chronic myeloid leukemia in chronic phase, a blood cancer characterized by the abnormal proliferation of white blood cells. It is a small molecule designed to target BCR-ABL. Terns Pharmaceuticals is evaluating it in a Phase 1/2 clinical study called CARDINAL.
TERN-701 targets BCR-ABL, a fusion protein that drives chronic myeloid leukemia. By inhibiting this protein, the drug aims to block the signaling that fuels the growth of leukemic cells. BCR-ABL is the defining molecular abnormality in CML and the established target of approved therapies for the disease.
TERN-701 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol TERN. The company is the sponsor of the CARDINAL study, the clinical trial evaluating the drug in patients with chronic myeloid leukemia.
TERN-701 is in Phase 2 development. The ongoing CARDINAL study is a Phase 1/2 clinical trial, and the program has reached the Phase 2 portion. The drug is investigational and has not been approved by the FDA for any indication. It has received Orphan Drug and Breakthrough Therapy designations from the FDA.
TERN-701 is being evaluated in the CARDINAL study, registered as NCT06163430. This Phase 1/2 trial is assessing the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in participants with chronic myeloid leukemia. The study is currently recruiting and plans to enroll approximately 180 participants.